The Clinical Trials Support Office (CTSO) was established in 2002 to provide support for clinical researchers at the three Fred Hutchinson/University of Washington Cancer Consortium (Consortium) institutions, which are Fred Hutchinson Cancer Research Center (FHCRC), University of Washington (UW), and Children's Hospital and Regional Medical Center (Children's). The overarching goal of the CTSO is to provide the infrastructure to support the conduct of efficient, high-quality, regulatorycompliant clinical trials within the Consortium. Toward this end, the CTSO provides centralized training and education to Cancer Consortium members and research staff on appropriate conduct of clinical trials. The CTSO also provides, on a fee-for-service basis, research study staff to implement and manage all aspects of clinical trials. The CTSO is responsible for the clinical trials monitoring program and for Protocol-Specific Research Support activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-39
Application #
8562017
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$310,205
Indirect Cost
$118,327
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications